S&P 500   3,257.90 (+0.35%)
DOW   26,840.51 (+0.09%)
QQQ   268.66 (+1.23%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
S&P 500   3,257.90 (+0.35%)
DOW   26,840.51 (+0.09%)
QQQ   268.66 (+1.23%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
S&P 500   3,257.90 (+0.35%)
DOW   26,840.51 (+0.09%)
QQQ   268.66 (+1.23%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
S&P 500   3,257.90 (+0.35%)
DOW   26,840.51 (+0.09%)
QQQ   268.66 (+1.23%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
Log in
NASDAQ:CMPI

Checkmate Pharmaceuticals Stock Forecast, Price & News

$9.80
-0.32 (-3.16 %)
(As of 09/25/2020 11:20 AM ET)
Add
Compare
Today's Range
$9.80
Now: $9.80
$10.49
50-Day Range N/A
52-Week Range
$8.61
Now: $9.80
$16.49
Volume408 shs
Average Volume96,470 shs
Market Capitalization$211.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.20 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMPI
CUSIPN/A
CIKN/A
Phone617-682-3625

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees22
Market Cap$211.16 million
Next Earnings Date12/18/2020 (Estimated)
OptionableNot Optionable
$9.80
-0.32 (-3.16 %)
(As of 09/25/2020 11:20 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for CMPI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Checkmate Pharmaceuticals (NASDAQ:CMPI) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Checkmate Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkmate Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Checkmate Pharmaceuticals
.

When is Checkmate Pharmaceuticals' next earnings date?

Checkmate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, December 18th 2020.
View our earnings forecast for Checkmate Pharmaceuticals
.

Who are some of Checkmate Pharmaceuticals' key competitors?

What other stocks do shareholders of Checkmate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkmate Pharmaceuticals investors own include Adobe (ADBE), Berkshire Hathaway (BRK.A), Lockheed Martin (LMT), Oak Street Health (OSH), Tesla (TSLA), Arena Pharmaceuticals (ARNA), Anthem (ANTM), Advanced Micro Devices (AMD), Albireo Pharma (ALBO) and Acutus Medical (AFIB).

Who are Checkmate Pharmaceuticals' key executives?

Checkmate Pharmaceuticals' management team includes the following people:
  • Mr. Barry A. Labinger, CEO, Pres & Director (Age 56, Pay $566.11k)
  • Dr. Arthur M. Krieg, Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director (Age 63, Pay $510k)
  • Ms. Karen Brennan, Chief Operating Officer (Age 64, Pay $446.25k)
  • Mr. Charles E. Yon, Co-Founder & Gen. Counsel (Age 70)
  • Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 50)

When did Checkmate Pharmaceuticals IPO?

(CMPI) raised $75 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets served as the underwriters for the IPO and BTIG was co-manager.

What is Checkmate Pharmaceuticals' stock symbol?

Checkmate Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMPI."

When did the company's quiet period expire?

Checkmate Pharmaceuticals' quiet period expired on Wednesday, September 16th. Checkmate Pharmaceuticals had issued 5,000,000 shares in its IPO on August 7th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Checkmate Pharmaceuticals?

Shares of CMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Checkmate Pharmaceuticals' stock price today?

One share of CMPI stock can currently be purchased for approximately $9.80.

How big of a company is Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals has a market capitalization of $211.16 million. Checkmate Pharmaceuticals employs 22 workers across the globe.

What is Checkmate Pharmaceuticals' official website?

The official website for Checkmate Pharmaceuticals is www.checkmatepharma.com.

How can I contact Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals' mailing address is 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-682-3625.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.